scholarly journals A three-dimensional in vitro dynamic micro-tissue model of cardiac scar formation

2018 ◽  
Vol 10 (3) ◽  
pp. 174-183 ◽  
Author(s):  
Paola Occhetta ◽  
Giuseppe Isu ◽  
Marta Lemme ◽  
Chiara Conficconi ◽  
Philipp Oertle ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Three Dimensional ◽  
Scar Formation ◽  
Fibroblast Proliferation ◽  
Tissue Model ◽  
Matrix Deposition ◽  
Extracellular Matrix Deposition ◽  
Mechanical Stretching

Our 3D-scar-on-a-chip model resembles fibroblast proliferation and activation, extracellular matrix deposition and stiffening upon application of only cyclic mechanical stretching.

Schwann Cell Differentiation in vitro: Extracellular Matrix Deposition and Interaction

1986 ◽  
Vol 8 (3) ◽  
pp. 182-196 ◽  
Author(s):  
A. Baron-Van Evercooren ◽  
A. Gansmüller ◽  
M. Gumpel ◽  
N. Baumann ◽  
H.K. Kleinman
Keyword(s):  
Extracellular Matrix ◽  
Cell Differentiation ◽  
Schwann Cell ◽  
Matrix Deposition ◽  
Extracellular Matrix Deposition ◽  
Schwann Cell Differentiation

scholarly journals Contribution of Fibroblasts to the Mechanical Stability of In Vitro Engineered Dermal-Like Tissue Through Extracellular Matrix Deposition

2014 ◽  
Vol 3 (5) ◽  
pp. 217-225 ◽  
Author(s):  
Renjith P. Nair ◽  
Jasmin Joseph ◽  
V.S. Harikrishnan ◽  
V.K. Krishnan ◽  
Lissy Krishnan
Keyword(s):  
Extracellular Matrix ◽  
Mechanical Stability ◽  
Matrix Deposition ◽  
Extracellular Matrix Deposition

scholarly journals GSK-3 Inhibition Modulates Metalloproteases in a Model of Lung Inflammation and Fibrosis

2021 ◽  
Vol 8 ◽  
Author(s):  
Francesco Cinetto ◽  
Jessica Ceccato ◽  
Ilaria Caputo ◽  
Daniela Cangiano ◽  
Barbara Montini ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Lung Inflammation ◽  
Therapeutic Strategy ◽  
Glycogen Synthase ◽  
Alveolar Cells ◽  
Human Lung Fibroblast ◽  
Matrix Deposition ◽  
Extracellular Matrix Deposition

Idiopathic pulmonary fibrosis (IPF) is mainly characterized by aberrant extracellular matrix deposition, consequent to epithelial lung injury and myofibroblast activation, and inflammatory response. Glycogen synthase kinase 3 (GSK-3) is a serine–threonine kinase involved in several pathways, and its inhibition has been already suggested as a therapeutic strategy for IPF patients. There is evidence that GSK-3 is able to induce matrix metalloproteinase (MMP) expression and that its inhibition modulates MMP expression in the tissues. The aim of our study was to investigate the role of GSK-3 and its inhibition in the modulation of MMP-9 and -2 in an in vivo mouse model of lung fibrosis and in vitro using different cell lines exposed to pro-inflammatory or pro-fibrotic stimuli. We found that GSK-3 inhibition down-modulates gene expression and protein levels of MMP-9, MMP-2, and their inhibitors TIMP-1 and TIMP-2 in inflammatory cells harvested from bronchoalveolar lavage fluid (BALF) of mice treated with bleomycin as well as in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells. To the same extent, GSK-3 inhibition blunted the increased MMP-9 and MMP-2 activity induced by pro-fibrotic stimuli in a human lung fibroblast cell line. Moreover, the αSMA protein level, a marker of fibroblast-to-myofibroblast transition involved in fibrosis, was decreased in primary fibroblasts treated with TGFβ following GSK-3 inhibition. Our results confirm the implication of GSK-3 in lung inflammation and fibrosis, suggesting that it might play its role by modulating MMP expression and activity but also pushing fibroblasts toward a myofibroblast phenotype and therefore enhancing extracellular matrix deposition. Thus, its inhibition could represent a possible therapeutic strategy.

Sign in / Sign up

Export Citation Format

Share Document